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Cervical human papillomavirus infection among
young women engaged in sex work in Phnom
Penh, Cambodia: prevalence, genotypes, risk
factors and association with HIV infection
Marie-Claude Couture1*, Kimberly Page1, Ellen S Stein1, Neth Sansothy2, Keo Sichan3, John Kaldor4,
Jennifer L Evans1, Lisa Maher4 and Joel Palefsky1
Abstract
Background: Although cervical cancer is the leading cancer in Cambodia, most women receive no routine
screening for cervical cancer and few treatment options exist. Moreover, nothing is known regarding the
prevalence of cervical HPV or the genotypes present among women in the country. Young sexually active women,
especially those with multiple sex partners are at highest risk of HPV infection. We examine the prevalence and
genotypes of cervical HPV, as well as the associated risk factors among young women engaged in sex work in
Phnom Penh, Cambodia.
Methods: We conducted a cross-sectional study among 220 young women (15–29 years) engaged in sex work in
different venues including brothels or entertainment establishments, and on a freelance basis in streets, parks and
private apartments. Cervical specimens were collected using standard cytobrush technique. HPV DNA was tested
for by polymerase chain reaction (PCR) and genotyping using type-specific probes for 29 individual HPV types,
as well as for a mixture of 10 less common HPV types. All participants were also screened for HIV status using
blood samples. Multivariate logistic regression analyses were conducted to assess risk factors for any or multiple
HPV infection.
Results: The prevalence of cervical HPV 41.1%. HPV 51 and 70 were the most common (5.0%), followed by
16 (4.6%), 71 (4.1%) and 81 (3.7%). Thirty-six women (16.4%) were infected with multiple genotypes and 23.3%
were infected with at least one oncogenic HPV type. In multivariate analyses, having HIV infection and a higher
number of sexual partners were associated with cervical HPV infection. Risk factors for infection with multiple
genotypes included working as freelance female sex workers (FSW) or in brothels, recent binge use of drugs,
high number of sexual partners, and HIV infection.
Conclusions: This is the first Cambodian study on cervical HPV prevalence and genotypes. We found that HPV
infection was common among young FSW, especially among women infected with HIV. These results underscore
the urgent need for accessible cervical cancer screening and treatment, as well as for a prophylactic vaccine
that covers the HPV subtypes present in Cambodia.
* Correspondence: mcouture@psg.ucsf.edu
1University of California San Francisco, Global Health Sciences, 50 Beale
street, Suite 1200, San Francisco, CA 94105, USA
Full list of author information is available at the end of the article
© 2012 Couture et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Couture et al. BMC Infectious Diseases 2012, 12:166
http://www.biomedcentral.com/1471-2334/12/166
Background
Cervical cancer is the third most common cause of can-
cer among women worldwide, and it is more frequent in
developing countries where population-level screening
programs are generally unavailable [1]. In Cambodia,
cervical cancer is the most common form of cancer
among women with an incidence (age-standardized rate
ASR) of 27.4 per 100 000, higher than in other Southeast
Asian countries [1]. Few, if any, Cambodian women
receive screening for cervical cancer and few treatment
options exist [2], likely contributing to a high mortality
rate of 16.2 per 100,000 (estimated age-standardized rate
ASR) [1].
Genital human papillomavirus (HPV), the most com-
mon sexually transmitted infection (STI) worldwide, is
the key causal agent in cervical cancer [3,4]. More than
100 different HPV genotypes have been identified, which
are divided into “high-risk” (HR) and “low-risk” (LR)
types on the basis of their oncogenic potential [5]. Most
HPV infections are transient and clinically unapparent.
However, persistent infection with cervical HR-HPV
genotypes can lead to the development of cervical cancer
pre-malignant lesions that may evolve into invasive cer-
vical cancer [5].
Cervical HPV prevalence and genotypes differ substan-
tially from one population to another worldwide. Although
cervical cancer is the leading cancer in Cambodia, nothing
is known regarding the prevalence of HPV infection or
the genotypic distribution in the country. As in other parts
of the world, epidemiological studies in Southeast Asia
has shown that the distribution of cervical HPV geno-
types differ across populations, and oncogenic genotypes
other than HPV-16 and −18 are frequent [6-10]. Two
commercial vaccines targeting oncogenic HPV-16 and
−18 have been shown to be efficacious in reducing both
chronic HPV infection, and cervical and vulvovaginal
disease related to these genotypes in women [11-13].
These two vaccines have been introduced in several
countries and are increasingly becoming available in
resource-constrained settings. However, their impact on
prevention of HPV infection and cervical cancer may
differ regionally, according to the genotype distribution.
Accurate epidemiological data on HPV prevalence and
genotypes in specific populations will assist public health
authorities to plan for immunization implementation,
and to guide future vaccine development.
Also of importance in planning clinical and public
health responses is an understanding of the factors asso-
ciated with acquiring cervical HPV infection. Factors
detected so far include higher number of sexual partners,
early age at first sexual intercourse, smoking, oral contra-
ceptive use, inconsistent condom use, and other STI infec-
tions, including HIV [14-17]. The literature has shown
that HIV-seropositive women are at greatly increased risk
for development of pre-malignant lesions and invasive
cervical cancer compared to HIV-seronegative women
[18-20]. Moreover, several studies have reported that the
prevalence of single or multiple HPV infections and
HPV viral load was higher among women infected with
HIV [19,21,22]. Women engaged in sex work have mul-
tiple sex partners, and are consequently at higher risk of
both HIV and HPV infection [6,9,23,24]. Understanding
the determinants of cervical HPV infection is an essential
step in developing effective interventions for the preven-
tion of infection, and ultimately cervical cancer.
To date, nothing is known regarding cervical HPV
prevalence, genotypic distribution, or risk factors in the
Cambodian female population. To inform policy and
guide further research, we undertook a study to examine
cervical HPV genotypes and the associated risk factors
among young FSW working in Phnom Penh, Cambodia.
Methods
Study setting
Cross-sectional data were obtained from a single baseline
visit, in the Young Women’s Health Study 2 (YWHS-2).
This prospective study, conducted from August 2009 to
August 2010, investigated HIV/STI, sexual behaviors and
drug use among women engaged in sex work in Phnom
Penh, Cambodia; methods described previously in detail
[25]. In brief, women working in brothels, entertainment
establishments or on a freelance basis were enrolled in a
one-year study, with quarterly follow-up visits to assess
HIV and HPV infections and associated risks. The study
was undertaken by a multi-disciplinary collaborative pre-
vention research group of academic, governmental and
community HIV prevention specialists from the U.S., Aus-
tralia, and Cambodia.
Study population and recruitment
A convenience sample of women engaged in sex work
was recruited through informational meetings, neighbor-
hood outreach, and referrals by participants. Inclusion
criteria for the study were: being female, aged 15–
29 years, ethnic Cambodian, reporting at least two dif-
ferent sexual partners in the last month or engagement
in transactional sex (sex in exchange for money, goods,
services, or drugs) in the last three months. Eligible
women who were interested in the study were invited to
a community location used by various sex-worker orga-
nizations, where they were provided with comprehensive
study information. A group informed consent process
including oral review of the written informed consent,
with explanations and opportunities for questions and
answers, was conducted. Women who consented to
participate were provided with appointment cards to
present to the YWHS clinic site. Free transportation was
offered to facilitate attendance at scheduled study visits.
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All women negative for HIV and not pregnant were
offered a three-dose regimen of a HPV quadrivalent
vaccine (GardasilTM).
Data collection
A structured paper questionnaire was administered in
Khmer by trained interviewers in a private room cover-
ing socio-demographic characteristics, occupational and
sexual risk, alcohol and drug use exposures. Client-
centered risk reduction counseling was provided, and
participants were offered testing for HIV and HPV. HIV
results were disclosed to participants and women infected
with HIV received counseling and were referred for free
medical evaluation and treatment, where indicated.
HPV and HIV testing
Cervical specimens were collected by a medical doctor
using a standard cytobrush technique and transported to
University of California at San Francisco for HPV test-
ing. HPV DNA was tested by polymerase chain reaction
(PCR) and genotyping was conducted using type-specific
probes [21,26]. MY09/MY11 primer and probe method
and Amplitaq Gold were used to amplify HPV sequences
[15,27]. Beta-globin primers were used as an internal
positive control for the presence of human DNA. As a
negative control, amplification of the reaction mixture
was performed with all components except the target
DNA. Samples were dot blotted and probed for HPV
DNA using a chemiluminescent procedure with a con-
sensus probe mixture. Samples determined to be
consensus-probe positive will then were reanalyzed for
the presence of 29 individual HPV types, as well as for a
mixture of 10 less common HPV types. Samples were
classified as HPV-positive or HPV-negative based on the
results of the consensus probe. If a sample was consen-
sus probe-positive but negative for all 39 HPV types, it
was considered to have an unknown HPV type. HPV
infection was classified as high risk (types 16, 18, 26/69,
31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 or 82)
or low risk (types 6, 11, 32/42, 54, 61, 62, 67, 70, 71, 72,
81, 83 or 84) based on strength of association of specific
HPV types with invasive cervical cancer[28].
HIV serology with venous blood was performed using
two rapid tests; Uni-Gold Recombigen (TM) HIV rapid
HIV test (Trinity Biotech USA, Jamestown, NY) and the
Clairview HIV 1/2 STAT-PAK (Inverness Medical Diag-
nostics, Waltham, MA). HIV-positive and discordant
samples were confirmed by HIV-1 immunoblot. HIV
specimen testing occurred at the Cambodian National
Institute of Public Health (NIPH) laboratory.
Ethical review
The study protocol was reviewed and approved by the
Cambodian National Ethical Committee, the Committee
on Human Research at UCSF and the University of New
South Wales Human Research Ethics Committee.
Measures
Outcome variables were “any HPV infection” and “mul-
tiple HPV infection” (two or more genotypes). Sociode-
mographic variables included age, marital status,
education and number of children. Based on sex work
activities in the past 30 days, women were classified as
working in either 1) entertainment establishments (beer
gardens, bars, karaoke, and night clubs) or 2) working
as freelance FSW in streets and parks or in brothels.
The promulgation of anti-sex-trafficking and sexual
exploitation laws enacted in 2008 has resulted in the
closure of brothels and the displacement of many FSW
to entertainment establishments or outdoor settings.
At the time this study was conducted (2009–2010) most
of the brothels were closed and only five women
reported working in brothels. Drug and alcohol use vari-
ables included recent (last 3 months) amphetamine-type
stimulants (ATS) use, recent binge use of drug, number
of days of alcohol use and the number of days drunk
(past month) [29]. Recent binge of drug was assessed by
asking participants if they had used any drugs for more
than 48 hours continuously without sleep in the last
3 months. Variables related to sexual behaviors included
age of first sexual intercourse, number of sexual partners
(last month), number of new sexual partners (last
month) and condom use with last paying and non-
paying partner. Condom use was classified as “consist-
ent” if the participant reported always using a condom.
Previously-diagnosed STI were assessed by asking parti-
cipants if a doctor, nurse, or other health care provider
had ever told them that they had been diagnosed with a
sexually transmitted infection.
Statistical analyses
Data were double entered into a database software
(Access, Microsoft Corp., Redmond, WA, USA) and
transferred into STATA 11.0 (STATA, College Station,
TX, USA) for statistical analyses. Bivariate logistic regres-
sion analyses were performed to identify associations
between socio-demographics, drug and alcohol use,
sexual behaviors, HIV and STI infections and HPV out-
comes: 1) “any HPV infection”, and 2) “multiple HPV
infection (≥2)”. Multivariate logistic regression models
were built according to a conceptual framework where
variables were entered as groups in steps [30]: 1) socio-
demographics; 2) drug and alcohol use; 3) sexual beha-
viors; 4) HIV and STI infections. First, sociodemographic
variables (group 1) with a level of significance in bivariate
analysis of p<0.20 were included in the model in a step-
wise backward approach, leading to our first model
including only sociodemographic variables associated
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with the outcome at p<0.10. Other variables were then
entered into the model in groups using the same step-
wise backward procedure, adjusting for the variable
included in the precedent model. In addition, variables
excluded in the earlier steps of the modeling were added
in the final model to assess their associations with the
outcome variable in the presence of the other variable or
their possible confounding effect. Only variables signifi-
cant at p<0.05, important confounders and potential
explanatory variables were retained in the final model.
Analyses were performed using STATA 11.0 (STATA,
College Station, TX).
Results
The prevalence of HIV was 15.8% among 220 participants.
Cervical HPV DNA was detected in 41.1% (90/220) of
women; HPV prevalence was 34.4% (64/186) among HIV
negative women and 78.8% (26/33) among those who
were HIV positive. Almost a quarter (23.2%) were infected
with at least one oncogenic high-risk (HR-HPV) genotype
and 17.7% with at least one low risk subtype (LR-HPV).
HPV-51 (5.0%; 11/220) and HPV-16 (4.6%; 10/220) were
the most common HR-HPV genotypes present, followed
by HPV-52 and HPV-53 (each 3.2%; 7/220). Among
those infected with LR-HPV genotypes, HPV-70 was the
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Figure 1 Prevalence of different cervical HPV genotypes among young women engaged in sex work participating in the Young
Women’s Health Study in Phnom Penh, Cambodia.
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most common (5.0%; 11/220), followed by HPV-71 (4.1%;
9/220) and HPV-81 (3.7%; 8/220) (Figure 1). Thirty-six
women (16.8%) were infected with multiple cervical HPV
genotypes and four women (1.8%) had five or more differ-
ent genotypes (Figure 2).
Table 1 shows sociodemographic characteristics, drug
and alcohol use, sexual behaviors, HIV and STI infec-
tions and their associations with any or multiple cervical
HPV infection. Participants’ median age was 26 years
(IQR 22, 28), almost a quarter (22.4%) had no education,
and 41.6% were widowed, divorced or separated. Women
reported working in sex work for a median of 3.5 years
(interquartile range (IQR 2.5, 6.3) and most (68.0%) were
working in the entertainment sector. Alcohol and ATS
use were prevalent. Median number of days drinking and
being drunk in the last month were 15 (IQR 4, 29) and 3
(IQR 0, 10) days, respectively), and the number of days
of drinking was inversely associated with prevalent HPV
(p≤ 0.05). Women who reported recent ATS use, includ-
ing binge use, had significantly higher risk of cervical
HPV infection (any or multiple). Women reported a
median of 6 (IQR 4, 15) sexual partners in the last
month and many were new (median = 3; IQR 1, 6). Con-
dom use during the last sexual intercourse was high with
paying partners (90.8%), but low with non-paying part-
ners (16.8%), mainly boyfriends and husbands. Almost
sixty percent (58.7%) reported ever been diagnosed
with a STI. The prevalence of any or multiple cervical
HPV infection was significantly (p≤ 0.01) higher among
women who worked as freelance in streets/parks or in
brothels (58.6% for any HPV and 33.8% for multiple
infection) compared with those working in entertainment
establishments (32.9% and 8.7%). FSW who reported
more sexual partners or new partners (≥16 compared to
less than 16) were more likely to have any or multiple
cervical HPV infection. The prevalence of HPV (any or
multiple) was significantly higher among HIV-infected
women and those who reported having had a previous
STI diagnosis (Table 1).
Table 2 shows multivariate logistic regression analyses
of risk factors for having any or multiple cervical HPV
infection. Of the sociodemographic and drug and alco-
hol use variables, only being a freelance or brothel-based
FSW and recent ATS use were significantly (p ≤ 0.05)
associated with having any HPV infection. However,
these associations were not non-significant when number
of sexual partners (last month) was entered in the model.
In the final multivariate model, higher number of sexual
partners (AOR 1.05; 95% CI: 1.01-1.09) and being
infected with HIV (AOR 7.96; 95% CI: 2.80-22.65) were
the only variables independently and significantly asso-
ciated with having any cervical HPV infection. Working
as a freelance FSW or in a brothel was significantly asso-
ciated with multiple cervical HPV infection types. How-
ever the association was attenuated when recent binge
use of drugs and number of sexual partners were entered
into the model. Reporting recent binge use of drug was
independently associated with having multiple cervical
HPV infection (AOR 3.45; 95% CI: 1.32-9.03), as was hav-
ing more sexual partners (AOR 1.09; 95% CI: 1.03-1.16)
and having HIV infection (AOR 5.25; 95% CI: 1.95-14.14).
Discussion
In this first epidemiological study of cervical HPV infec-
tion in Cambodia, we found that HPV infection was
common (41.1%) among women engaged in sex work in
Phnom Penh. The prevalence of cervical HPV is com-
parable to that observed in FSW in Japan (48%)[31],
Korea (47%)[23], Tunisia 43.8%[32], Senegal (43%)[33],
and Bulgaria (43.4%)[34], but somewhat lower than
other locales including Vietnam (85%)[6], Kenya (55.6%)
[35], Peru 65.8%[36] and the Philippines (57.2%)[9]. The
mean age of FSW in these studies ranged from 24–
31 years old, similar to our study (mean 26 years old).
Variations in cervical HPV prevalence reported by these
studies may be attributable to the use of different HPV
assays, differences in FSW populations, or sampling. The
high cervical HPV prevalence found among women
engaged in sex working Phnom Penh likely reflects
increased sexual exposure, that could lead to higher risk
of cervical cancer in this vulnerable population.
In this population of Cambodian FSW, HPV-51 was
the most prevalent oncogenic genotype, followed by
HPV-16. Other dominant HR-HPV genotypes included
HPV-52 and HPV-53, while prevalence of HPV-18 was
lower. HPV-70, HPV-71 and HPV-81 were the most fre-
quent low-risk genotypes observed. This is consistent
with other epidemiological studies conducted in South-
east Asia where infection with oncogenic genotypes such
as HPV-51 and HPV-52 was common [6-10]. However,
a wide variation in genotype distribution has been
Figure 2 Prevalence of infection with multiple cervical HPV
genotypes among young women engaged in sex work
participating in the Young Women’s Health Study in Phnom
Penh, Cambodia.
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Table 1 Characteristics and prevalence of any and multiple cervical HPV infection among women engaged in sex work
participating in the Young Women’s Health Study in Phnom Penh, Cambodia
Characteristic Prevalence of
characteristic
Prevalence of any HPV infection Prevalence of multiple HPV
(≥2 genotypes) infection
N (%) N (%) OR (95% CI) N (%) OR (95% CI)
Overall 220 90 (41.1) 37 (16.8)
Sociodemographics
Age (years): Median 26; IQR (22, 28) 1.00 (0.93-1.08)† 1.04 (0.94-1.15) †
16-18 14 (6.4) 5 (35.7) 1.0 1 (7.1) 1.0
19-24 71 (32.4) 29 (40.9) 1.20 (0.36-3.95) 11 (15.5) 2.38 (0.28-20.11)
25-29 134 (42.8) 56 (41.8) 1.31 (0.42-4.13) 25 (18.5) 2.95 (0.37-23.64)
Education (years): Median 4; IQR (1, 6) 0.93 (0.85-1.02) † 0.93 (0.82-1.05)
None 49 (22.4) 23 (46.9) 1.0 12 (24.0) 1.0
Primary (1–6 years) 124 (56.6) 54 (43.6) 0.85 (0.44-1.67) 20 (16.0) 0.60 (0.27-1.35)
Secondary (7+ years) 46 (21.1) 13 (28.3) 0.46 (0.20-1.08) 5 (11.1) 0.40 (0.13-1.23)
Marital status
Never married 44 (20.1) 22 (50.0) 1.0 8 (17.8) 1.0
Married-living together 84 (38.4) 36 (35.2) 0.75 (0.36-1.56) 18 (21.4) 1.26 (0.50-3.18)
Widowed/Divorced/Separated 91 (41.6) 32 (42.9) 0.54 (0.26-1.13) 11 (12.1) 0.64 (0.24-1.71)
Number of child: Median 1; IQR (0, 1) 0.80 (0.59-1.09) † 1.08 (0.74-1.58) †
0 89 (40.6) 43 (48.3) 1.0 16 (17.8) 1.0
1 78 (35.6) 28 (35.9) 0.60 (0.32-1.15) 11 (14.1) 0.76 (0.33-1.75)
More than 2 52 (23.7) 19 (36.5) 0.54 (0.26-1.13) 10 (19.2) 1.10 (0.46-2.64)
Type of sex venue (last 30 days)
Entertainment 149 (68.0) 49 (32.9) 1.0 13 (8.7) 1.0
Freelances/brothels 70 (32.0) 41 (58.6) 2.89 (1.61-5.18)** 24 (33.8) 5.34 (2.52-11.33)**
Drug and alcohol use
ATS use (last 3 months)
No 160 (72.7) 53 (33.1) 1.0 18 (11.3) 1.0
Yes 60 (27.3) 37 (62.7) 3.40 (1.82-6.32)** 19 (31.7) 3.66 (1.76-7.60)**
Binge of drugs (last 3 months)
No 179 (81.7) 65 (36.3) 1.0 22 (12.3) 1.0
Yes 40 (18.3) 25 (62.5) 2.93 (1.44-5.94)** 15 (36.6) 4.12 (1.89-8.95)**
Number of days of drinking alcohol (last month): 0.98 (0.95-0.99) †* 0.97 (0.94-0.99) †*
0 – 4 57 (26.5) 32 (56.1) 1.0 16 (27.6) 1.0
5 – 19 57 (25.9) 20 (35.1) 0.40 (0.19-0.86) †* 8 (14.3) 0.44 (0.17-1.12)
> 20 105 (47.7) 38 (36.2) 0.45 (0.24-0.88) †* 13 (12.3) 0.37 (0.16-0.83)*
Number of days drunk (last month): 0.99 (0.95-1.03) 0.98 (0.93-1.03)
0 – 4 123 (56.2) 57 (46.3) 1.0 27 (21.8) 1.0
5 – 19 72 (32.9) 22 (30.6) 0.51 (0.28-0.94) †* 6 (8.3) 0.33 (0.13-0.83)*
> 20 24 (11.0) 11 (45.8) 0.98 (0.41-2.36) 4 (16.7) 0.72 (0.23-2.28)
Sexual behaviors
Age at first sexual intercourse
≤ 15 37 (16.9) 19 (51.4) 1.0 8 (21.6) 1.0
> 15 180 (82.2) 70 (38.9) 1.00 (0.97-1.04) 28 (15.5) 1.02 (0.99-1.05)
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observed in different Southeast Asian countries; HPV-16
was most commonly detected in Thailand and Vietnam,
but the second most frequent in Indonesia and Philip-
pines [7]. Similar to Cambodia, HPV-18 was the fourth
most common oncogenic HPV genotype in normal cy-
tology in Vietnam, and HPV-51 was the most frequently
observed genotype in Indonesia [7,37]. This indicates
that many HR-HPV genotypes other than HPV-16 and
HPV-18 may play important roles in cervical carcino-
genesis in Cambodia, and elsewhere in Southeast Asia.
Two commercial HPV vaccines targeting only oncogenic
HPV-16 and HPV-18 (Gardasil™ and Cervarix™) have
been approved by national regulatory agencies and are
currently used in several countries. To date, Cervarix™ is
the only vaccine that has been approved in Cambodia
but access is limited. Our results and those from other
epidemiological studies clearly show that currently avail-
able vaccines do not cover the most prevalent HR-HPV
genotypes found in Cambodia and other Southeast Asian
countries. However, some cross-protection with other
HPV subtypes has been observed for Cervarix™[38,39].
These findings underscore the potential limited impact
of existing HPV vaccines on cervical cancer prevention
in Southeast Asia, despite the cross protection that has
been observed [11].
Consistent with previous studies, women infected with
HIV were more likely to be infected with any cervical
HPV genotype compared with HIV-negative women.
[21,22,40]. Simultaneous infection with multiple cervical
HPV genotypes was also higher among women infected
with HIV, which is consistent with other studies [35,40].
A possible explanation is that HIV and HPV are both
sexually transmitted infections, sharing common modes
of transmission. Biological mechanisms involving the
immune system might also be implicated; the immune
response elicited by HPV infection and associated clear-
ance of HPV infection, could predispose women to
HIV acquisition [41-43]. Thus, women in the process of
clearing an HPV infection might be at higher risk of HIV
infection [44]. Immunosuppression caused by HIV infec-
tion can also increase susceptibility to viral acquisition,
lead to inability to clear HPV infection or potentiate
reactivation of latent HPV infections [18,22]. Persistent
cervical HPV infection is a major cause of cervical cancer
and the fact that it is more common among HIV-infected
women makes primary prevention by immunization prior
to acquisition of HPV more crucial. Two recent studies
have shown that the quadrivalent vaccine Gardasil™ was
safe and immunogenic in cohorts of HIV-infected chil-
dren and men infected with HIV [45,46].
Table 1 Characteristics and prevalence of any and multiple cervical HPV infection among women engaged in sex work
participating in the Young Women’s Health Study in Phnom Penh, Cambodia (Continued)
Number of sexual partners (last month): 1.06 (1.03-1.09) †** 1.06 (1.03-1.09) †**
≤5 99 (45.2) 31 (31.3) 1.0 9 (9.1) 1.0
6 – 15 71 (32.4) 27 (38.0) 1.35 (0.71-2.55) 8 (11.3) 1.27 (0.46-3.47)
≥ 16 49 (22.4) 32 (65.3) 4.13 (2.00-8.53)** 20 (40.0) 6.67 (2.74-16.21)**
Number of new partners (last month): 1.09 (1.04-1.14) †**
0 43 (19.6) 16 (37.2) 1.0 4 (9.3) 1.0
1-5 120 (54.8) 40 (33.3) 0.85 (0.41-1.74) 18 (14.8) 1.70 (0.54-5.35)
>6 56 (25.6) 34 (60.1) 2.61 (1.15-5.91)* 25 (26.8) 3.57 (1.09-11.69)*
Condom use with last paying partner
Consistent (always) 197 (90.8) 83 (42.1) 1.0 33 (16.7) 1.0
Inconsistent 20 (9.2) 6 (30.0) 0.59 (0.22-1.60) 3 (15.0) 0.88 (0.24-3.18)
Condom use with last non- paying partner
Consistent (always) 18 (16.8) 7 (38.9) 1.0 2 (11.1) 1.0
Inconsistent 89 (83.2) 34 (38.2) 0.97 (0.34-2.75) 12 (13.5) 1.25 (0.25-6.12)
HIV and STI infections
HIV result
Negative 186 (84.9) 64 (34.4) 1.0 22 (11.8) 1.0
Positive 33 (15.1) 26 (78.8) 7.08 (2.91-17.20)** 15 (44.1) 5.89 (2.62-13.23)**
Previously diagnosed STI
No 91 (41.7) 29 (31.9) 1.0 12 (13.2) 1.60 (0.76-3.38)
Yes 127 (58.3) 61 (48.) 1.98 (1.13-3.47)* 25 (19.5)
† = variable use as continuous * = p≤ 0.05 ** = p≤ 0.01.
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This is the first study to show that recent binge use of
ATS is associated with multiple HPV genotypes, even
after controlling for sexual behaviors, HIV and STI
infection. ATS use has emerged as a potential significant
problem among FSW in Cambodia, and Southeast Asia
more generally [29,47]. ATS has been associated with
incident STI, including HIV among many groups [48,49]
including FSW [29,50,51]. ATS users are at higher risk
of STIs due to their risky sexual behaviors, but also
because of their exposure to social networks with high
HIV/STI prevalence. Drug use, especially stimulant use,
has also been linked to perturbations of the immune
Table 2 Variables independently associated with prevalence of any (A) or multiple (B) cervical HPV infection among
women engaged in sex work participating in the Young Women’s Health Study in Phnom Penh, Cambodia (n = 220)
A. Any HPV infection
Model 1 Model 2 Model 3 Final model
Variables AOR (95% CI) AOR (95% CI) AOR (95% CI) AOR (95% CI)
Sociodemographics
Number of child 0.77 (0.56-1.05)† 0.84 (0.61-1.16)† 0.80 (0.57-1.11)† 0.70 (0.49-1.01)†
Type of sex venue (last 30 days)
Entertainment/others 1.0 1.0 1.0 1.0
Freelances/brothels 3.00 (1.66-5.43)** 2.11 (1.08-4.12)* 1.30 (0.60-2.84) 0.77 (0.32-1.88)
Drugs and alcohol use
ATS use (last 3 months)
No 1.0 1.0 1.0
Yes 2.27 (1.11-4.62)* 1.85 (0.88-3.89) 1.85 (0.83-4.12)
Sexual behaviors
Number of sexual partners (last month) 1.05 (1.01-1.08)†* 1.05 (1.01-1.09)†*
HIV and STI infections
Previously diagnosed STI
No 1.0
Yes 1.55 (0.82-2.92)
HIV result
Negative 1.0
Positive 7.96 (2.80-22.65)**
B. Multiple HPV infection (≥2 genotypes)
Model 1 Model 2 Model 3 Final Model}
Variables OR (95% CI) AOR (95% CI) AOR (95% CI) AOR (95% CI)
Sociodemographics
Type of sex venue (last 30 days)
Entertainment/others 1.0 1.0 1.0 1.0
Freelances/brothels 5.34 (2.52-11.33)** 4.18 (1.90-9.21)** 3.56 (1.44-8.82)** 3.05 (1.05-8.84)*
Drugs and alcohol use
Binge of drugs (last 3 months)
No 1.0 1.0 1.0
Yes 2.58 (1.12-5.96)* 2.66 (1.09-6.51)** 3.45 (1.32-9.03)*
Sexual behaviors
Number of sexual partners (last month) 1.07 (1.02-1.13)†** 1.09 (1.03-1.16)†**
Number of new sexual partners (last month) 0.91 (0.84-0.99)†* 0.90 (0.82-0.99)†*
HIV result
Negative 1.0
Positive 5.25 (1.95-14.14)**
† = variable use as continuous } = Final model adjusted for education * = p≤ 0.05 ** = p≤ 0.01.
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system in both animal models and humans, possibly
leading to increased risk of HIV and STI infection
[52-56]. A recent study has shown that cocaine use was
associated with increased risk of oncogenic and nonon-
cogenic HPV infection among women [57]. The mechan-
isms by which ATS is associated with increased risk of
HPV infection is unknown but the immune response to
HPV infection might be altered by the use of stimulants
such as cocaine and ATS. HIV-infected women are
already immunosuppressed and prone to numerous co
infections. ATS use combined with HIV seropositivity
could synergistically act on suppression of the immune
system and increase susceptibility to HPV infection. Fur-
ther clinical and laboratory research is needed to better
understand the immunomodulatory effects of stimulants
on HPV infection and the underlying mechanisms in a
context of high HIV prevalence.
Women working as freelance FSW or in brothels were
at higher risk of being infected with multiple cervical
HPV genotypes. Our group and others have shown
that these women are more susceptible to HIV and STI
infection compared with their counterparts working in
entertainment and service venues [25,58,59]. Sex work
environments influence behaviors, and FSW working as
freelancers or in brothels may engage in riskier sexual
practices, be more likely to use drugs, and have a greater
likelihood of having HIV or STI infected partners. In
our study, prevalence of any or multiple cervical HPV
infection increased with the number of sexual partners
reported by FSW, a finding that has been well docu-
mented by others [15,16].
Our study has several limitations. The cross-sectional
design of this study does not permit us to conclude
causality between HPV infection and risk factors studied
here with certainty, as experimental design would.
Cervical HPV may not necessarily represent total HPV
infection, which can also include oral, vaginal/vulvar,
and anal HPV. Self-reported data on sexual behaviors
and drug use may introduce response bias associated
with socially acceptable or desired answers. Measuring
condom use with the last partner might not be represen-
tative of general condom use behaviors. However, this
would result in conservative estimates of risk, biasing
our results toward the null. Finally, participants in this
study were not sampled probabilistically; as a conse-
quence our rresults may not be generalizable to all
young women in sex work in Phnom Penh or Cambodia.
Nevertheless, our sample included women from a wide
range of sex work venues and captured a wide breadth
of this high-risk occupational group in Phnom Penh.
Conclusions
Our findings highlight the burden of cervical HPV infec-
tion among FSW in Phnom Penh and, in particular the
vulnerability of women infected with HIV and those
using ATS. Routine screening for cervical cancer is not
available for most Cambodian women and few if any
treatment options exist upon diagnosis with pre-
malignant lesions or cervical cancer. These first results
on prevalence of cervical HPV infection and the geno-
types present among Cambodian women offer important
insights into the need for cervical cancer screening
strategies and immunization programs in this country.
However, more epidemiological research is needed to
examine HPV infection at a population level in Cambo-
dia and, in particular to inform the development of
effective prevention interventions for young and high-
risk women. Paying for sex is widely accepted among
men in Cambodia and the number of women engaged in
sex work has grown substantially in the past few years;
estimated at 34,193 [60]. Finally, our findings underscore
the urgent need of for accessible HPV and cervical
cancer prevention and treatment, as well as the import-
ance of combining prevention and treatment of drug use
with HIV prevention and reproductive health interven-
tion programs targeting FSW in Cambodia.
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